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Key messages
What is already known about this subject?
 ► among inflammatory/dysimmune myopathies 
(iDMs), dermatomyositis (DM) is the only associated 
with type i-interferon signature.
 ► Most iDMs are associated with myofiber expression 
of major histocompatibility complex (MHc)-class i. 
MHc-i is induced by interferons suggesting a possi-
ble role for type ii-interferon in iDMs other than DM.
What does this study add?
 ► in this study, we showed that myofiber MHc-ii ex-
pression is observed in inclusion body myositis (iBM) 
and antisynthetase myositis (aSM), but not in DM 
and necrotizing autoimmune myopathy (naM).
 ► in accordance with this finding, we showed that iBM 
and aSM are specifically associated with type-ii iFnγ 
signature, DM only with type-i iFn signature, and 
naM with neither type-i nor type-ii iFn signature.
How might this impact on clinical practice?
 ► Distinct iFn signatures allow a more distinct seg-
regation of iDMs and therefore a more accurate 
diagnosis.
 ► Deciphering iFn signatures in iDMs will also lead to 
develop new therapeutic approaches targeting iFns 
pathways.
AbstrAct
Objective the role of interferons (iFn) in the 
pathophysiology of primary inflammatory and dysimmune 
myopathies (iDM) is increasingly investigated, notably 
because specific neutralisation approaches may constitute 
promising therapeutic tracks. in present work we analysed 
the muscular expression of specific iFnα/β and iFnγ-
stimulated genes in patients with various types of iDM.
Methods 39 patients with iDM with inclusion body 
myositis (iBM, n=9), dermatomyositis (DM, n=10), 
necrotising autoimmune myopathies (naM, n=10) and 
antisynthetase myositis (aSM, n=10), and 10 controls were 
included. Quantification of expression levels of iFnγ, iSg15, 
an iFnα/β-inducible gene and of six iFnγ-inducible genes 
(gBP2, Hla-DOB, Hla-DPB, ciita, Hla-DrB and Hla-DMB) 
was performed on muscle biopsy samples.
Results DM usually associated with strong type i iFnα/β 
signature, iBM and aSM with prominent type ii iFnγ 
signature and naM with neither type i nor type ii iFn 
signature. immunofluorescence study in aSM and iBM 
showed myofibre expression of major histocompatibility 
class 2 (MHc-2) and ciita, confirming the induction of the 
iFnγ pathway. Furthermore, MHc-2-positive myofibres 
were observed in close proximity to cD8+ t cells which 
produce high levels of iFnγ.
Conclusion Distinct iFn signatures allow a more distinct 
segregation of iDMs and myofibre MHc-2 expression is a 
reliable biomarker of type ii iFn signature.
InTROduCTIOn
Both muscle biopsy and circulating myosi-
tis-specific autoantibodies (MSA) are used 
in the diagnostic workup for inflammatory 
and dysimmune myopathies (IDM). Muscle 
biopsy made possible to visualise and clas-
sify the pathological processes leading to 
myofibre injuries, such as CD8 T cell-medi-
ated cytotoxicity in inclusion body myositis 
(IBM), endomysial microangiopathy with 
ischaemic myofibre injuries in dermato-
myositis (DM) and complement-mediated 
myofibre necrosis in necrotising autoimmune 
myopathies (NAM).1 MSAs had a major impli-
cation in delineation of distinctive patterns of 
disease or phenotype and in predicting prog-
nosis of IDMs.2 In addition, the role of inter-
ferons (IFN) in the pathophysiology of IDMs 
is increasingly scrutinised in a therapeutic 
perspective,3 notably because it may lead to 
specific IFN neutralisation approaches.4 For 
example, DM displays a strong type I IFNα/β 
signature.5 6 In contrast to DM, the role of 
IFNs has not been well established in other 
types of IDM.7
In a previous study on anti-synthetase 
syndrome-associated myositis (ASM), a condi-
tion in which muscular involvement is asso-
ciated with peculiar extramuscular features 
and specific circulating autoantibodies, we 
observed that, in contrast to DM, there was 
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conspicuous myofibre expression of major histocompati-
bility class 2 (MHC-2) antigens.7 Since MHC-2 expression 
by myogenic cells is induced by type II IFNγ and blocked 
by type I IFNα/β,8 marked MHC-2 expression in ASM 
suggested imbalance between IFN type I and type II path-
ways in favour of IFN type II in this specific IDM subtype. 
In the present study, type I and type II IFN signatures 
were determined in muscle biopsy samples from patients 
with the main IDM subtypes, including DM, IBM, NAM 
and ASM. Expression analysis of specific IFNα/β and 
IFNγ-stimulated genes characterised DM as specifically 
associated with type I IFNα/β signature, IBM and ASM 
with type II IFNγ signature and NAM with neither type I 
nor type II IFN signature.
MaTeRIals and MeTHOds
Patients and muscle samples
Muscle biopsies from patients with NAM (n=10), DM 
(n=10), ASM (n=10), IBM (n=9) and histologically 
normal muscle (n=10, controls) were obtained from 
the Department of Pathology, Henri Mondor University 
Hospital (Créteil, France). A polymyositis (PM) group 
was not included because of the extreme rarity of idio-
pathic PM when strict diagnostic criteria are used. This 
study was conducted in accordance with French rules 
(Henri Mondor Biological Resource Platform: registra-
tion number DC-2009-930, French Ministry of Research). 
Autoantibodies screening was carried out using commer-
cially available linear dots. All patients had muscle biopsy 
for diagnostic purposes, with immunoperoxidase staining 
of MHC-1 and MHC-2 antigens, complement membrane 
attack complex (C5b-9), CD56/NCAM (myofibre regen-
eration), CD68 (macrophages), and CD3, CD4, CD8 
and CD20 (leucocyte subsets), and immunofluorescence 
for dual labelling (MHC-2/class II MHC transactivator 
(CIITA); MHC-2/CD8) (references in online supple-
mentary information). European Neuromuscular Centre 
(ENMC) criteria were used to diagnose DM, NAM and 
IBM, and Troyanov classification was used to diagnose 
overlap myositis,1 the ASM subset of which being defined 
by detection of circulating antisynthetase autoantibodies. 
Myofibre MHC-2 expression was defined by sarcolemmal 
staining with or without sarcoplasmic staining.7
Real-time quantitative PCR
RNAs were extracted from biopsy samples using Trizol 
reagent and quantified by NanoDrop. cDNAs were 
synthesised using the Maxima First strand cDNA synthesis 
kit (Thermo Scientific). We analysed the expression 
levels of IFNγ, ISG15, an IFNα/β-inducible gene and of 
six IFNγ-inducible genes: GBP2, HLA-DOB, HLA-DPB, 
CIITA, HLA-DRB and HLA-DMB. We used quantitative 
RT-PCR on ABI PRISM 7900HT using TaqMan assays 
(Applied Biosystems) or the SYBR Green reagent. Assays 
and primer sequences are indicated in online supple-
mentary information). The median fold change in 
expression of six IFNγ-stimulated genes for each patient 
biopsy sample was used to define an IFNγ score.9
statistical analysis
Statistical analyses were performed using the non-para-
metric Mann-Whitney test (p<0.05 was considered signif-
icant) and GraphPad Prism V.6.0 (GraphPad Software, 
La Jolla, CA).
ResulTs
Patient characteristics
Patients with ASM included four women and six men 
(mean age: 55 years; range: 25–83), with anti-Jo1 autoan-
tibodies in 9/10 and anti-PL7 in 1/10. Patients with DM 
included eight women and two men (mean age: 58 years; 
range: 34–85), and patients with IBM included four 
women and five men (mean age: 69 years; range 61–89). 
Patients with NAM included eight women and two men 
(mean age: 54 years; range 24–90), with anti-signal recog-
nition particle autoantibodies in 3/10, anti-HMGCR in 
3/10 and anti-Ku in 1/10.
IFnα/β-inducible gene expression in muscle tissues
We first tested the involvement of type I IFNα/β in the 
various IDM subsets by quantifying the level of ISG15 
expression, an IFNα/β-inducible gene in muscle. ISG15 
expression was markedly and specifically increased in DM: 
DM versus NAM: p<0.0001; DM versus ASM: p<0.0001; 
DM versus IBM: p<0.0001 (figure 1H).
expression IFnγ and its inducible genes in muscle tissue
IFNγ expression in muscle varied according to each IDM 
subtype. The highest levels of IFNγ were observed in 
patients with IBM followed by patients with ASM, whereas 
IFNγ expression was detectable at low level in DM, and 
absent (comparable to controls) in NAM (figure 1A).
Consistently expression of the IFNγ-inducible CIITA 
gene tended to be higher in ASM and IBM compared 
with NAM and DM (figure 1B). Immunohistochemical 
expression of the IFNγ-inducible MHC-2 differed between 
ASM and IBM, mainly perifascicular in ASM and multi-
focal in IBM (figure 2). Expression levels of HLA-DOB 
and HLA-DPB genes were significantly higher in IBM 
compared with NAM (p=0.0039 and p=0.0002, respec-
tively) (figure 1E,F), and in ASM compared with NAM 
(p=0.0027 and p=0.0051, respectively) (figure 1E,F). 
Expression levels of HLA-DRB genes were significantly 
higher in IBM compared with NAM (p=0.0433) but not 
in ASM (figure 1C). Increased HLA-DPB gene expression 
could segregate both IBM and ASM from DM (p=0.002 
and p=0.0028, respectively) (figure 1F). HLA-DQ gene 
expression level fell beneath the detection threshold. In 
contrast, increased GBP2 gene expression could discrim-
inate both IBM and ASM from NAM (p=0.0524 and 
p=0.0021, respectively), and ASM from DM (p=0.0062) 
(figure 1G).
In line with these results, the IFNγ score defined by the 
median fold change in expression of six IFNγ-induced 
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Figure 1 Relative expression of IFNγ (A), CIITA (B), HLA-
DRB (C), HLA-DMB (D), HLA-DOB (E), HLA-DPB (F), GBP2 
(G) and ISG15 (H) in NAM, DM, ASM and IBM. *P<0.05; 
**P<0.01; ***P<0.001. ASM, anti-synthetase syndrome-
associated myositis; DM, dermatomyositis; IBM, inclusion 
body myositis; IFN, interferon; NAM, necrotising autoimmune 
myopathies; RQ, relative quantification.
Figure 2 Muscle biopsy from a patient with inclusion 
body myositis (IBM). (A–C) Immunofluorescence staining of 
major histocompatibility class 2 (MHC-2) and CIITA: MHC-
2, red (A); CIITA, green (C); merged with DAPI for nuclei 
staining in blue (B). The pattern of MHC-2-positive myofibre 
distribution appears multifocal. Double staining shows 
CIITA-positive/MHC-2-negative myofibres corresponding 
to an early step of interferon-γ (IFNγ) signalling, double-
positive CIITA/MHC-2 fibres (stars) indicating early MHC-2 
transactivation and CIITA-negative/MHC-2-positive fibres 
indicating later stages, concomitant with CIITA degradation. 
(D–F) Immunofluorescence staining of MHC-2 and CD8: 
MHC-2, red (D); CD8, green (F); merged with DAPI for nuclei 
staining in blue (E). CD8+ T cells are found proximal to MHC-
2-positive myofibres, MHC-2 expression by CD8 T cells 
(double-stained cells), (E) indicating activated state. Frozen 
muscle sections (7 µm). Magnification ×10.
Figure 3 IFN score calculated from the median fold change 
in expression of six IFNγ-induced genes (CIITA, HLA-
DRB, HLA-DMB, HLA-DOB, HLA-DPB, GBP2).13 *P<0.05; 
**P<0.01; ***P<0.001. IFN, interferon.
genes clearly discriminated ASM and IBM from NAM 
(p=0.0022 and p=0.0022, respectively) and ASM and 
IBM from DM (p=0.0411 and p=0.0043).(figure 3) Taken 
together, these data were consistent with an IFNγ signa-
ture in ASM and IBM.
IFnγ pathway activation in myofibres
The respective localisation of MHC-2 and CIITA expres-
sions was assessed by immunofluorescence in IDM subsets 
with elevated IFNγ score, that is, ASM and IBM. In ASM, 
MHC-2 and CIITA expressions were primarily observed 
in perifascicular myofibres (figure 2A). Most myofi-
bres coexpressed MHC-2 and CIITA, with occasional 
fibre expression MHC-2 or CIITA alone (figure 2A). 
In contrast, in IBM, MHC-2-positive myofibres were 
distributed in multifocal clusters that coexpressed CIITA 
(figure 2A). CD8-positive cells known to produce IFNγ 
were usually observed in the vicinity of MHC-2-positive 
myofibres (figure 2B). In DM, only few MHC-2-positive 
myofibres were observed. In NAM, no myofibre MHC-2 
expression was observed, and no or very few CD8-positive 
cells were detected in the endomysium.
dIsCussIOn
Many reports have reported type I IFNα/β signature 
in muscle and blood of patients with DM.10 11 Consist-
ently, the type I IFN-inducible ISG15 gene expression 
was upregulated in muscle of our patients with DM as 
previously documented by microarray analyses in whole 
muscle5 12 or microdissected MHC-1-positive myofibres.13 
4 rigolet M, et al. RMD Open 2019;5:e000811. doi:10.1136/rmdopen-2018-000811
RMD Open
In DM, perifascicular atrophic fibres also strongly express 
MxA protein, an important type I IFN-related factor.5 
The inducer of type I IFN release is unknown in DM, 
but IFNα and β are known to be produced by plasma-
cytoid dendritic cells that are increased in DM muscle.5 
Type I IFNs have been recognised to play key roles in the 
initiation and maintenance of the DM process, through 
exacerbation of inflammatory responses,14 upregulation 
of MHC-1 in myofibres, effects on endothelial cells5 and 
induction of mitochondrial dysfunction.15
To assess type II IFN, we used a panel of genes including 
IFNγ, CIITA, GBP2 and four MHC-2 genes. This combi-
nation was chosen to focus on genes electively induced 
by IFNγ despite highly weight with MHC-2-related tran-
scripts. Other IFNγ-induced genes could be used such as 
GBP5, ICAM1, CAMK2D, IRF1, SOCS3, CD44 or CCL2.16 
In accordance with the existence of CD8-positive large 
granular lymphocytes in sIBM,10 we showed that type II 
IFN signature was electively increased in sIBM. IFNγ is a 
potent inducer of MHC-2 expression,7 an effect mediated 
by the transactivator CIITA.11 Increased muscle expres-
sion of IFNγ in ASM and IBM was associated with both 
CIITA gene upregulation and myofibre expression of 
MHC-2 antigens. In DM, the type II signature was low but 
not null, in keeping with the presence of few numbers of 
MHC-2-positive myofibres.7 Previous studies investigating 
myofibre MHC-2 expression in DM17 18 showed a median 
percentage of MHC-2-positive fibres ranging from 2.2% to 
8.6%,17 a proportion similar to that we reported (7.5%)7 
and indicating that type I and type II signatures may occa-
sionally overlap in DM. In contrast, NAM expressed virtu-
ally no type I or type II IFN signature and no MHC-2 in 
myofibres, a feature in agreement with current view of 
NAM pathogenesis highlighting a role for autoantibodies 
and complement activation in myofibre injuries.193
The main sources of IFNγ are natural killer (NK) cells, 
CD4-Th1 and CD8-cytotoxic T lymphocytes.20 In addi-
tion to type II IFN signature, we observed CD8+ T cells 
in close vicinity of MHC-2 expressing myofibres in both 
ASM and IBM (figure 3). NK cells are rare in muscular 
inflammatory infiltrates in ASM21 and virtually absent in 
IBM.22 This finding points out CD8+ T cells as a likely 
source of local IFNγ production in ASM and IBM. In 
sIBM, IFNγ signalling cascade was shown upregulated in 
attacked myofibres but not in non-attacked supporting 
this view.23 Expression of CIITA protein was restricted to 
myofibres in ASM and IBM (figure 2A). In addition to 
inducing MHC-2, and possibly MHC-1 myofibre expres-
sion, IFNγ may also inhibit myogenesis through CIITA by 
recruiting myogenin together with silencing epigenetic 
factors to target gene promoters.24 So, IFNγ activity may 
both sustain inflammation and impair injured myofibre 
repair, and therefore could aggravate the MHC-1/
TCR-mediated myofibre destruction by CD8 T cells.
We hope that the distinctive IFN signatures in the 
different IDM subtypes reported herein could help in 
further development of key molecular pathway-based 
therapeutic approaches, targeting IFN type I in DM,3 25 
IFN type II in ASM and IBM, and complement-mediated 
cell death in NAM.26
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